Eric Nybo

Dr. Eric Nybo

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2016 in The Plant Cell
Verified
Journal Article
Open access
PDF file
SKSantosh kumar
Santosh kumar
CKChase Kempinski
Chase Kempinski
XZXun Zhuang
Xun Zhuang
ANAyla Norris
Ayla Norris
SMSibongile Mafu
Sibongile Mafu
JCJoe Chappell
Joe Chappell
Marchantia polymorpha, like all liverworts, accumulates a large array of terpenes, and this process depends on a unique family of terpene synthases.

30 December 2022 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
CBClaudine E. Bayles
Claudine E. Bayles
DHDanielle E. Hale
Danielle E. Hale
AKAli Konieczny
Ali Konieczny
VAVeronica D. Anderson
Veronica D. Anderson
CRClaire R. Richardson
Claire R. Richardson
ENEric Nybo
Eric Nybo

3 August 2016 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
JSJacqueline Saunders
Jacqueline Saunders
KMKayla Maki
Kayla Maki
RKRenee Koski
Renee Koski
ENEric Nybo
Eric Nybo
Fungal diseases of the nail bed (onychomycosis) and epidermis are recurrent illnesses in the elderly and immunocompromised patients, which have few efficacious treatment options. Current treatment options for onychomycosis are limited to topical agents, laser treatment, and oral antifungals. Previous generations of topical agents were not efficacious, owing to poor penetration of the nail bed. Oral antifungal drugs, such as itraconazole, terbinafine, and fluconazole, not only give better response rates but also inhibit a host of CYP450 enzymes. Oral antifungals can exacerbate drug–drug interactions for patients taking other medications concurrently. Newer topical agents might recognize improved efficacy and provide therapeutic alternatives when the use of oral antifungal agents is contraindicated. Recently, the Food and Drug Administration (FDA) approved efinaconazole and tavaborole for the treatment of onychomycosis. Additionally, the FDA approved luliconazole for the treatment of tinea pedis, tinea cruris, and tinea corporis. This review examines the mechanism of action, spectrum of activity, pharmacokinetics, and clinical trials data and considers the place in therapy for these 3 new antimycotic agents.

1 June 2020 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
ENEric Nybo
Eric Nybo
SKStephanie A. Klepser
Stephanie A. Klepser
MKMichael E Klepser
Michael E Klepser

1 November 2020 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
ENEric Nybo
Eric Nybo
Michelle KellyMichelle Kelly
Michelle Kelly
MYMark Young
Mark Young
KAKatie Axford
Katie Axford
MSMinji Sohn
Minji Sohn
MKMichael E Klepser
Michael E Klepser

1 November 2017 in Journal of Biotechnology
Verified
Journal Article
Closed access
ENEric Nybo
Eric Nybo
JSJacqueline Saunders
Jacqueline Saunders
SMSean P. McCormick
Sean P. McCormick